The Cross-Border Biotech Blog

MondayDealTitle-514x270

Welcome to your Monday Biotech Deal Review for June 22nd & 29th, 2015! In M&A news, Tribute Pharmaceuticals Canada Inc. kicked off the summer with the $25 million acquisition of Medical Futures, with Tribute concurrently raising $12.5 million in a private placement of secured subordinated debentures. In addition, M Pharmaceuticals completed the acquisition of Trimtec […]

read more


CSRFeatImg

Welcome to your Canada in Science Review for June 19th, 2015! Cancer Cell. 2015 Jun 8;27(6):864-876. Inhibition of the Mitochondrial Protease ClpP as a Therapeutic Strategy for Human Acute Myeloid Leukemia.   Proc Natl Acad Sci U S A. 2015 Jun 8. pii: 201500857. TOE1 is an inhibitor of HIV-1 replication with cell-penetrating capability.   Nat Med. 2015 Jun […]

read more


BBB_Part11_Logo

Cost-Effectiveness and Affordability of New Medicines (4) Can individuals, healthcare payers and society in general afford to pay for all of the new diagnostics, drugs and medical procedures?   In the last blog, I concluded that the use of the new Hepatitis C drugs was cost-effective in the patient groups in which it had been […]

read more


MondayDealTitle-514x270

Welcome to your Monday Biotech Deal Review for June 15th, 2015! This week, InSite Vision announced that it will be acquired in an all-stock transaction by QLT Inc., a Vancouver-based biotech company specializing in ocular products. In financing news, Endo International PLC closed its previously reported share offering, generating gross proceeds of $2.3 billion. Continue […]

read more


MondayDealTitle-514x270

Welcome to your Monday Biotech Deal Review for June 8th, 2015! *A day late, but here is the Monday Deal Review for June 8th. This week, POZEN Inc. made a splash with the announcement of its US $146 million acquisition of Tribute Pharmaceuticals Canada Inc.. Meanwhile, several companies were active in the securities markets, with  […]

read more


CSRFeatImg

Welcome to your Canada in Science Review for June 5th, 2015! Mucosal Immunol. 2015 Jun 3. doi: 10.1038/mi.2015.46. A critical role for cellular inhibitor of protein 2 (cIAP2) in colitis-associated colorectal cancer and intestinal homeostasis mediated by the inflammasome and survival pathways.   Cell Metab. 2015 Jun 2;21(6):883-890. AMPK Activation of Muscle Autophagy Prevents Fasting-Induced Hypoglycemia and […]

read more


BBB_Part10_Logo

Cost-Effectiveness and Affordability of New Medicines (3) The cost-effectiveness of treatments for chronic medical conditions is much more difficult to assess than for acute medical conditions. I am going to mention two groups of drugs, those used for modifying blood cholesterol levels and those used to treat hepatitis C.   Statins The following quotations are […]

read more


MondayDealTitle-514x270

Welcome to your Monday Biotech Deal Review for June 1st, 2015! ProMetic Life Sciences was very active in this last week of May. The Laval, Québec based company announced the acquisition of Emergent Bio Solutions in addition to the receipt of over $7.5 million from the exercising of an over-allotment option from a previous securities […]

read more


MondayDealTitle-514x270

Welcome to your Monday Biotech Deal Review for May 25th, 2015! The past week saw Endo International announce the acquisition of Par Pharmaceutical holdings in a $8 billion deal, creating a speciality pharmaceutical company with a generics business. For details this story, as well as for the rest of the week’s news, continue reading the […]

read more


CSRFeatImg

Welcome to your Canada in Science Review for May 22nd, 2015! Cell Rep. 2015 May 21. doi: 10.1016/j.celrep.2015.04.056 Single Transcription Factor Conversion of Human Blood Fate to NPCs with CNS and PNS Developmental Capacity   BMC Biotechnol. 2015 May 16;15(1):31. Critical assessment of influenza VLP production in Sf9 and HEK293 expression systems.   Dev Cell. 2015 May 13. […]

read more